12:00 AM
 | 
Apr 04, 2011
 |  BC Week In Review  |  Company News  |  Deals

Cephalon, Champions Biotechnology deal

Champions will use its Biomerk Tumorgraft technology to evaluate the efficacy of Cephalon's CEP-37440 for cancer. The Tumorgraft technology uses implantation of human tumors in immune deficient mice to...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >